Intensifying competition and technological change in biotechnology
First written in FY2016. 13 of 15 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug, genomic research, and cancer precision medicine markets. - FY2025RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug, genomic research, and cancer precision medicine markets. - FY2023-Q3RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2023-Q1RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2022-Q3RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2022-Q1RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2021-Q3RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2021-Q2RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2021-Q1RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments.」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2020-Q3RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2020-Q2RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2020-Q1RestatedAnnual report
「Such market expansion is also considered likely to lead to an increase in the number of market entrants and potential competitors, while collaboration across industries could lead to rapid advances in technological innovation and other developments」
The company continues to disclose the risks of increasing market entrants, intensifying competition, and technological change accompanying the expansion of the anticancer drug and cancer precision medicine markets. - FY2018WorsenedAnnual report
「In addition, in the cancer precision medicine business, the market is expected to expand going forward, and the number of new market entrants is expected to increase.」
The company explicitly identifies the risks of new market entrants and intensifying competition in the cancer precision medicine business, in addition to conventional genomic research and drug discovery. - FY2017RestatedAnnual report
「If the company becomes unable to respond to research results and other developments considered potentially useful in pharmaceutical research and development due to rapid advances in research or other factors, this could have a material adverse effect on the business development of the Group.」
The company continues to treat technological change, intensifying competition, and difficulty responding to research results in the biotechnology sector as risks. - FY2016First statedAnnual report
「If the company becomes unable to respond to research results and other developments considered potentially useful in pharmaceutical research and development due to rapid advances in research or other factors, this could have a material adverse effect on the business development of the Group.」
The company recognizes as external risks the increasing number of companies entering the field of genomic research, competition based on speed, and technological innovation through collaboration across industries.